Zydus Lifesciences share price
You have to be logged in to add this to Watchlist.- ₹1,090.45(-1.26%)June 15, 2026 15:29:52 PM IST
- NSE
- BSE
- Vol : 1.17 M (NSE + BSE)Last 20 day avg : 2.51 M
Zydus Lifesciences is trading -1.26% lower at Rs 1,090.45 as compared to its last closing price. Zydus Lifesciences has been trading in the price range of 1,110.90 & 1,086.00. There are 30 analysts who have initiated coverage on Zydus Lifesciences. There are 6 analysts who have given it a strong buy rating & 9 analysts have given it a buy rating. 3 analysts have given the stock a sell rating.The company posted a net profit of 1,272.50 Crores in its last quarter.Listed peers of Zydus Lifesciences include Cipla (-0.49%), Torrent Pharmaceuticals (-1.44%), Divi's Laboratories (-0.38%).The Mutual Fund holding in Zydus Lifesciences was at 4.88% in 31 Mar 2026. The MF holding has increased from the last quarter. The FII holding in Zydus Lifesciences was at 6.95% in 31 Mar 2026. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Updated on Jun 15, 2026, 11:10 PM UTC
- BetaLow volatility0.52Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.46The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.09Annual dividends as a percentage of the stock price.
- PEG RatioIndicates undervaluation0.68The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
|
| ||||
|
| ||||
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Cipla | Neutral | 1,382.00 | -0.49 | 1,11,638.04 | 22.95 | 3.87 | 0.87 | 0.81 |
| Torrent Pharmaceuticals | Bullish | 4,508.95 | -1.44 | 1,52,528.87 | 67.32 | 17.1 | 0.83 | 17.62 |
| Divi's Laboratories | Bullish | 6,608.15 | -0.38 | 1,75,538.10 | 78.61 | 11.52 | 0.46 | 0.01 |
| Dr Reddy's Laboratories | Bullish | 1,280.00 | 0.48 | 1,06,839.48 | 18.63 | 3.14 | 0.63 | 2.34 |
| Sun Pharmaceutical Industries | Bullish | 1,800.00 | -0.40 | 4,31,870.12 | 36.24 | 5.77 | 0.92 | 0.50 |
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-05-19 | Audited Results, Dividend & Buy Back |
| 2026-02-09 | Quarterly Results |
| 2025-11-06 | Quarterly Results & Fund raising |
| 2025-08-12 | Quarterly Results |
| 2025-05-20 | Audited Results & Final Dividend |
- IndustryBiotechnology & Drugs
- ISININE010B01027
- BSE Code532321
- NSE CodeZYDUSLIFE
Zydus Lifesciences is trading at 1090.45 as on Mon Jun 15 2026 09:59:52. This is -1.26% lower as compared to its previous closing price of 1104.35.
The market capitalization of Zydus Lifesciences is 109724.78 Cr as on Mon Jun 15 2026 09:59:52.
The average broker rating on Zydus Lifesciences is Buy. The breakup of analyst rating is given below -
- 6 analysts have given a strong buy rating
- 9 analysts have given a buy rating
- 10 analysts have given a hold rating
- 3 analysts have given a sell rating
- 2 analysts have given a strong sell rating
The 52 wk high for Zydus Lifesciences is 1119.00 whereas the 52 wk low is 835.85
Zydus Lifesciences can be analyzed on the following key metrics -
- TTM P/E:
- Sector P/E: -
- Dividend Yield: %
- D/E ratio: -
Zydus Lifesciences reported a net profit of 4523.40 Cr in 2026.
The Mutual Fund Shareholding was 4.88% at the end of 31 Mar 2026.
EQUITY QUICK LINKS
Zydus Lifesciences QUICK LINKS
FROM MARKETS
RELATED LINKS
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.